Kiadis receives $3.9M boost for blood cancer trial

06/27/2013 | Genetic Engineering & Biotechnology News

A division of the Netherlands' Ministry of Economic Affairs granted Kiadis Pharma a loan worth around $3.9 million to support midstage trials of ATIR. The drug candidate is designed to permit stem cell transplantations for blood cancer patients with partially mismatched or haploidentical donors.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR